Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Huperzine A vs Sage: Huperzine A has the stronger overall evidence (6 vs 6/10); they're alternatives for sharpen focus — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Huperzine A wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Too few graded studies
1 of 2 studies with measurable effects showed benefit.
Top outcomes
Verdict
Too few graded studies
1 of 1 studies with measurable effects showed benefit.
Top outcomes
Shared outcomes (1)
Outcomes where both Huperzine A and Sage have evidence — compare verdict strength side-by-side.
50-200mcg twice daily
Morning and early afternoon, Avoid evening (may cause vivid dreams)
Huperzine A capsules (standardized extract)
300–600 mg standardized extract daily
With breakfast, With dinner (split dosing)
Standardized extract (300–600 mg, 2.5% rosmarinic acid)
and 1 more not shown
and 4 more not shown
2-4 weeks
30-60 minutes
2-4 weeks
During use
4–8 weeks
4–8 weeks
4–8 weeks
8–12 weeks
The treatment of cognitive dysfunction in dementia: a multiple treatments meta-analysis
Psychopharmacology (2018) · Meta analysis · n=44854
The pooled standardized mean difference of the treatment effects on cognitive dysfunction was 0.439 (95% confidence interval 0.374, 0.504).
Traditional Chinese herbal medicine for vascular dementia
The Cochrane database of systematic reviews (2018) · Systematic review · n=3581
Two TCHMs (NaoMaiTai and TongXinLuo) had a 5% or more increased risk of AEs compared to the 'no Treatment' control, but the quality of this evidence was poor.
Interventions to delay functional decline in people with dementia: a systematic review of systematic reviews
BMJ open (2016) · Systematic review · n=70
The quality of the reviews varied; however most (65%) scored 8/11 or more on the AMSTAR tool, indicating high quality.
Systematic review of clinical trials assessing pharmacological properties of Salvia species on memory, cognitive impairment and Alzheimer's disease.
CNS Neuroscience & Therapeutics (2014) · Systematic review
Eight clinical studies were included: six on cognitive performance in healthy subjects and two on Alzheimer's disease.
Exploring the therapeutic impact of Salvia officinalis on lipid and oxidative stress markers in patients with polycystic ovary syndrome - a randomized placebo-controlled clinical trial.
BMC Complementary Medicine and Therapies (2025) · Rct · n=70
70 women with newly diagnosed PCOS were randomized to receive either 330 mg of S. officinalis extract or placebo daily for eight weeks.
Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease
J Clin Pharm Ther (2003) · Rct · n=42
42 patients aged 65-80 with mild to moderate Alzheimer's disease were randomized to a fixed dose of S. officinalis extract (60 drops/day) or placebo for 4 months.
Doses are per day. At 200 mcg (0.1 mg twice daily), a double-blind trial in 78 people with mild to moderate vascular dementia improved MMSE, CDR and daily living scores over 12 weeks (PMID 21833673). At 400 mcg (200 mcg twice daily), the primary analysis of a phase II trial in 210 people with Alzheimer's disease found no effect on ADAS-Cog at 16 weeks, so the curve stays flat rather than rising (PMID 21502597). At 800 mcg (400 mcg twice daily), the same trial found a 2.27-point ADAS-Cog gain at 11 weeks that was no longer significant at 16 weeks. A meta-analysis of four trials using 300 to 500 mcg a day found MMSE and daily living gains (PMID 19221692). The trials are in different populations and only one compared doses, so no minimum, optimal or safe ceiling is set.
Based on multiple RCTs showing improvements in word recall, working memory, and attention. Effects varied by specific cognitive domain and population. Most studies used standardized extracts.
AI-estimated from published studies. Interpret as directional guidance.
Huperzine A has a higher evidence score (6/10 vs 6/10) and wins in 2 of 3 categories.
For sharpen focus, Huperzine A has a higher relevance score (80 vs 70).
No documented interaction was found in the data searched. This does not establish that this exact combination is safe.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.